Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flexyn2a
- Development stage
- Phase 2
- Lead developer
- LimmaTech Biologics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Flexyn2a is a bioconjugate vaccine designed to protect against infection by *Shigella flexneri* 2a. It consists of the O-polysaccharide antigen from *S. flexneri* 2a enzymatically linked to the exotoxin A (EPA) protein from *Pseudomonas aeruginosa* using an in vivo conjugation process in *Escherichia coli*. The resulting conjugate stimulates an immune response targeting the lipopolysaccharide (LPS) of *S. flexneri* 2a and has demonstrated robust immunogenicity and protective efficacy in clinical trials. Flexyn2a is administered intramuscularly and can be formulated with or without alum adjuvant[1][3][6]. The vaccine was originally developed by GlycoVaxyn and further advanced by LimmaTech Biologics in collaboration with Johns Hopkins Bloomberg School of Public Health[7]. Its primary indication is for the prevention of shigellosis caused by *S. flexneri* 2a.
- Other names
- Shigella 4VShigella4VShigella-4VShigella dysenteriae bioconjugate vaccine - GlycoVaxynShigella flexneri 2a vaccine - GlycoVaxynShigella vaccine - LimmaTech Biologics
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on Flexyn2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flexyn2a.